Big Board

Content Ideas
Result Content Idea Research
Result Content Idea Research
1 DMARDs for Patients With Rheumatoid Arthritis-Associated ILD
2 Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease
3 Assessing Rates and Risk Factors for Interstitial Lung Disease in Patients With Rheumatoid Arthritis
4 Researchers Find HRCT Risk Prediction Model Helpful in Predicting RA-ILD Prognosis
5 Perceptions, Practices in RA-ILD Differ Between Rheumatologists and Pulmonologists
6 Homocitrullination May Be Linked to Interstitial Lung Disease in Rheumatoid Arthritis
7 Methotrexate does not increase risk for rheumatoid arthritis-associated ILD
8 Interstitial lung disease exacerbates rheumatoid arthritis activity, related conditions
9 Methotrexate Not Associated with Lung Disease in RA
10 Genetic variant in Japanese population increases risk of interstitial lung disease among RA patients
11 FDA Approves New Treatment for Chronic Fibrosing ILD
12 No Link Between Methotrexate, Interstitial Lung Disease in RA
13 Treatment with methotrexate and risk of lung disease in patients with rheumatoid arthritis
14 Year in review: New treatment options, updates in ILD, IPF
15 Rheumatoid Arthritis Extra-Articular Manifestations: Challenges of Interstitial Lung Disease
16 Rheumatoid arthritis-associated interstitial lung disease: an overview of epidemiology, pathogenesis and management.
17 Survival After Acute Flares of Interstitial Lung Disease Varies by Fibrosis Type, Study Says
18 Prevalence of interstitial lung disease in RA increased from 2003 to 2014
19 Lung Disease in RA: Which Factors are Linked With Mortality?
20 Rheumatoid Arthritis Treatment Doesn't Harm Lungs: Study
21 Nintedanib approval provides 'exciting news' for other CTD-associated ILD
22 FDA Approves First Treatment for Group of Progressive Interstitial Lung Diseases
23 Rheumatoid Arthritis-Associated Interstitial Lung Disease: Clinical Characteristics and Predictors of Mortality
24 MTX Not Associated With Increased Interstitial Lung Disease Risk in RA
25 Rheumatoid arthritis treatment doesn't damage lungs, study shows
26 Lung Cancer Risk in Rheumatoid Arthritis: An Update
27 Complementary therapies can 'harmonize' with RA treatment
28 Lung Disease Tied to Rheumatoid Arthritis Safely Treated with Rituximab, Study Finds
29 Current Perspectives On Emerging Biomarkers For Rheumatoid Arthritis-A | OARRR
30 Upadacitinib superior to methotrexate in treating rheumatoid arthritis
31 The Lung in RA: Little Progress
32 Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) 2020-2028
33 In Certain ILD Patients, Ofev Slows Lung Function Decline, Trial Finds
34 Abatacept, TNF inhibitors linked to similar rates of pulmonary exacerbation in RA patients
35 IPF, Lung Disease In Rheumatoid Arthritis Share Genetic Risk Factor
36 Autoimmune lung disease: Early recognition and treatment helps
37 Rituximab May Help in RA Lung Disease
38 Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) Forecasts to 2028: 7MM Coverage, Epidemiology Segmentation, Drugs Update and Competitor Insights
39 Interdisciplinary Medicine Is Best in Rheumatology
40 People With Rheumatoid Arthritis Have a Risk of Interstitial Lung Disease
41 eLearning Expands Osteoporosis Care for Underserved Communities
42 Current therapies, guidelines inadequate to manage CV events in rheumatic diseases
43 Global Market Outlook and Epidemiology for Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) 2020-2028
44 Treprostinil Improves Walk Distance in Pulmonary Hypertension
45 Overview of Idiopathic Pulmonary Fibrosis, Evidence-Based Guidelines, and Recent Developments in the Treatment Landscape
46 Rheumatoid lung disease: Symptoms, diagnosis, and treatment
47 The Not So Golden Age of Rheumatology Therapy
48 Methotrexate not an additional risk factor for interstitial lung diseases in RA
49 Failure to 'move the needle' in OA driving joint replacement boom
50 Performance of Administrative Algorithms to Identify Interstitial Lung Disease in Rheumatoid Arthritis
51 Rheumatologists value patient-reported RA symptoms over test results
52 High-dose trivalent flu vaccine safe, more immunogenic than standard dose in RA
53 Global trends emerge in chronic respiratory disease mortality, disability
54 Many patients with RA fail to modify treatment despite high disease activity
55 Pirfenidone promising for unclassifiable ILD
56 Rheumatologists or primary care: Who bears 'responsibility' for CV risk?
57 Rheumatoid Arthritis and Cognitive Impairment
58 Patients with rheumatic disease, COVID-19 more likely to require ventilation
59 Ambient Respiratory Viral Infections Linked to Incident RA Diagnoses
60 ASGE to hold virtual, interactive endoscopy postgraduate course
61 Signal fault wreaks havoc on rush hour Glasgow trains
62 ACE inhibitors heighten risk of renal crisis in systemic sclerosis
63 Ninfetanib Improves and Stabilizes Lung Function in Systemic Sclerosis
64 Rheumatoid arthritis may start in the lungs rather than joints
65 Interstitial pneumonia may be new category of undifferentiated connective tissue disease
66 Comorbidities Pose Challenges in Treating RA
67 VIDEO: Interstitial lung disease on the rise in patients with RA, despite better control of RA
68 Gadolinium-enhanced MRI improves diagnostic accuracy in polymyalgia rheumatica
69 RA BIODAM Resources Validate Rheumatoid Arthritis Biomarkers
70 PsA diagnosis often delayed in dermatology vs. rheumatology
71 Liver Fibrosis, Stiffness Rates in Rheumatoid Arthritis and Methotrexate Therapy
72 Stem cell transplant, Rituxan hold 'tremendous promise' for ILD with systemic sclerosis
73 New analyses of Ofev data in patients with chronic fibrosing ILD
74 Success, event rates similar after PCI for in-stent, de novo CTO
75 New Treatment Option for Systemic Sclerosis-Associated Interstitial Lung Disease
76 Infection risk similar for TNF inhibitors plus methotrexate, triple therapy in RA
77 Can you die from rheumatoid arthritis? Lifespan and outlook
78 9 Types of Interstitial Lung Disease
79 For IBD-associated arthritis, disease control is becoming a team sport
80 Upadacitinib outperforms adalimumab in methotrexate-refractory RA
81 Pulmonary fibrosis and rheumatoid arthritis: What's the link?
82 Effect of tumor necrosis factor inhibitors on interstitial lung diseas | DDDT
83 Number of prior DMARDs, disease duration linked to diminished drug response in RA
84 Common genetic link found in lung conditions, study finds
85 Rheumatologists, patients share common barriers to controlling RA
86 Genentech's Esbriet gets FDA breakthrough status in uILD
87 Treatment recommendations for RA in cancer fail to meet criteria
88 RA risk increased up to fivefold among patients with high CCP levels
89 Blood test for RA biomarker launched
90 RV to LV Diameter Ratio May Predict Mortality in Interstitial Lung Disease
91 Heart and Lung Disease and Other Complications Start Early in Rheumatoid Arthritis
92 Protecting Your Lungs With Rheumatoid Arthritis
93 Treatment Options for Rheumatoid Fibrosing Alveolitis
94 No difference in effectiveness between Xeljanz, non-TNF biologics in RA
95 RheumNow: Interstitial Lung Disease Not Increased With Biologics
96 Atyr's potential $175M deal with Kyorin bILD-ing the case for lead sarcoidosis candidate
97 Ace the Case: A 55-Year-Old Man With RA and Increasing Joint Symptoms After Methotrexate Use
98 Rheumatologists vary on when to discontinue arthritis drugs during unplanned pregnancies
99 Mild, stable interstitial lung disease symptoms present in about half of patients with MCTD
100 Tocilizumab's CV risk comparable to that of etanercept, other RA biologics